Skip to main content
. 2012 May 9;7(5):e36722. doi: 10.1371/journal.pone.0036722

Figure 1. Genetic variants among the cisplatin-sensitive and -resistant ovarian cancer cells.

Figure 1

(A) Western blotting was performed for the expression variations of prosurvival Bcl-2, Bcl-xL and Mcl-1 and proapoptotic Bak and Bax proteins among the cisplatin-sensitive (A2780s, IGROV1 and OAW42) and -resistant (A2780cp, OVCAR-3 and SKOV3) ovarian cancer cells. β-actin was used as a loading control. (B) A2780s (p53 WT) and SKOV3 (p53 -/-) cells were treated with cisplatin (5 µg/mL) for 24 hours and analyzed for the expression of p53, p73, p21waf1/cip1, NOXA and Bax by Western blotting. β-actin was used as a loading control. (C) OVCAR3 (harboring mutant p53 R248Q) and A2780cp (containing p53 wild-type gene sequence but showing loss of p53 function) cells were treated with cisplatin (5 µg/mL) for 24 hours and analyzed for the expression of p53, p73, p21waf1/cip1, NOXA and Bax by Western blotting. β-actin was used as a loading control.